11
May

Commit up to $485 million to buy a cancer genomics company. Pay another $450 million for a share of an immuno-oncology candidate. Throw in a $30 million licensing deal and an $80 million bet on a longtime collaborator and you’ve got a month in the life of Celgene, biotech’s most prolific dealmaker.

…read more

Source: Celgene’s R&D speed dating is starting to pay off, CEO says

    

0 No comments